- Home
- COGT vs CHY Comparison
COGT vs CHY Comparison
Compare COGT & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- CHY
- Stock Information
- Founded
- COGT 2014
- CHY 2003
- Country
- COGT United States
- CHY United States
- Employees
- COGT N/A
- CHY N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- COGT Health Care
- CHY Finance
- Exchange
- COGT Nasdaq
- CHY Nasdaq
- Market Cap
- COGT 1.0B
- CHY 934.9M
- IPO Year
- COGT 2018
- CHY N/A
- Fundamental
- Price
- COGT $6.48
- CHY $10.24
- Analyst Decision
- COGT Buy
- CHY
- Analyst Count
- COGT 7
- CHY 0
- Target Price
- COGT $14.17
- CHY N/A
- AVG Volume (30 Days)
- COGT 1.0M
- CHY 128.3K
- Earning Date
- COGT 05-06-2025
- CHY 01-01-0001
- Dividend Yield
- COGT N/A
- CHY 10.11%
- EPS Growth
- COGT N/A
- CHY N/A
- EPS
- COGT N/A
- CHY N/A
- Revenue
- COGT N/A
- CHY N/A
- Revenue This Year
- COGT N/A
- CHY N/A
- Revenue Next Year
- COGT N/A
- CHY N/A
- P/E Ratio
- COGT N/A
- CHY N/A
- Revenue Growth
- COGT N/A
- CHY N/A
- 52 Week Low
- COGT $5.88
- CHY $9.97
- 52 Week High
- COGT $12.61
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- COGT 38.02
- CHY 33.53
- Support Level
- COGT $6.31
- CHY $10.27
- Resistance Level
- COGT $7.49
- CHY $10.60
- Average True Range (ATR)
- COGT 0.43
- CHY 0.17
- MACD
- COGT -0.04
- CHY 0.03
- Stochastic Oscillator
- COGT 10.90
- CHY 30.77
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.